1211443-61-6Relevant articles and documents
Synthesis method of ribociclib intermediate product and intermediate compound thereof
-
Paragraph 0089-0091, (2020/05/14)
The invention discloses a synthesis method of a ribociclib intermediate product, which comprises the following steps: by using barbituric acid as a starting material, carrying out chlorination and formylation to obtain a compound 2; and performing condens
POLYMORPHS OF 7-CYCLOPENTYL-N,N-DIMETHYL-2-{[5-(PIPERAZIN-1-YL) PYRIDIN-2-YL]-AMINO}-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THE PREPARATION THEREOF
-
Page/Page column 25-27, (2020/11/12)
The present invention relates to novel crystalline forms of butanedioic acid 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide of formula-1a and process for preparation thereof. The present invention also relates to a process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide. Further, the present application also relates to acid addition salts of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide and process for the preparation thereof.
CDK9 inhibitor, preparation method and application thereof
-
Paragraph 0106-0107; 0115-0116, (2021/01/04)
The invention provides a CDK9 inhibitor, the CDK9 inhibitor is a pyrimidopyrrole kinase inhibitor, and the chemical structural general formula of the CDK9 inhibitor is shown as the formula I in the specification, the CDK9 inhibitor is the pyrimidopyrrole kinase inhibitor, the protein target adapted to the pyrimidopyrrole kinase is serine/threonine kinase CDK9. The CDK9 inhibitor shows relatively high specificity and low cytotoxicity, and the CDK9 inhibitor which is used for preventing or treating tumor growth and metastasis, has selectivity on CDK9, and is small in toxic and side effects and strong in action effect is provided, so that the CDK9 inhibitor is used for regulating and controlling the biological function of CDK9 and inhibiting the growth and proliferation processes of tumors.
AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB SUCCINATE AND ITS NOVEL CRYSTALLINE FORMS THEREOF
-
Page/Page column 19-20, (2019/08/08)
The present invention relates to an improved process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate (1/1) compound of formula-1a and its novel crystalline for
Key intermediate for synthesis of CDK 4/6 dual inhibitor and preparation method and application of key intermediate
-
Paragraph 0119; 0122-0125; 0128-0131; 0134-0137; 0141-0143, (2019/08/20)
The invention discloses a 2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-methanamide intermediate and a preparation method and application thereof. The intermediate is the compoundI, and the preparation method comprises the following st
Synthesis method of antineoplastic drug ribociclib intermediate
-
Paragraph 0032; 0061-0078, (2019/11/13)
The invention relates to a synthesis method of an antineoplastic drug ribociclib intermediate. The synthesis method includes the following steps that the electrophilic addition reaction is conducted on N,N-dimethylacrylamide and bromine to obtain N,N-dime
Synthesis method of anti-tumor drug ribociclib
-
Paragraph 0041; 0081-0098, (2019/11/14)
The invention relates to a synthesis method of an anti-tumor drug ribociclib. The method mainly comprises the steps of carrying out a reaction between 4-(6-amino-3-pyridyl)-1-piperazinyl tert-butyl formate and 2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrol
SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
-
Paragraph 0109; 0114; 0115, (2019/02/09)
The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
New intermediate of ribociclib, and synthetic method for preparing ribociclib by using new intermediate
-
Paragraph 0098; 0099, (2018/10/19)
The invention provides a new intermediate compound 6 of ribociclib, and a preparation method thereof, and a synthetic method for preparing ribociclib by using the new intermediate compound 6, whereinthe structure of the compound 6 is defined in the specif
THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN, AND CHECKPOINT INHIBITORS
-
Paragraph 0218, (2018/08/20)
The invention relates to compounds and methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis. Type 1 or 2 diabetes, obesity, inflammatory disease, o